Haemolytic uraemic syndrome

  • D. K
  • T. G
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Atypical haemolytic uraemic syndrome (aHUS) is a disease characterized by complement overactivation in which inherited defects in complement genes and acquired autoantibodies against complement regulatory proteins have been described. Identification of the underlying defect can both predict disease outcome and guide treatment. The ability to remove inhibitory autoantibodies and hyper-active complement components in addition to its ability to replace defective complement regulators means that plasma exchange is currently first-line therapy. In those with factor H and factor I mutations who do progress to end-stage renal failure, renal transplantation usually fails due to recurrent HUS. In this situation, combined liver-kidney transplantation has been suggested to correct the underlying genetic defect. Newer agents, such as the complement inhibitor eculizumab, may herald a new era in the treatment of aHUS. Copyright © 2010 S. Karger AG, Basel.

Author-supplied keywords

  • acetylsalicylic acid
  • antioxidant
  • autoantibody
  • complement activation
  • complement factor H
  • eculizumab
  • fibrinogen
  • fresh frozen plasma
  • gene mutation
  • genetic disorder
  • hemolytic uremic syndrome
  • heparin
  • human
  • kidney failure
  • kidney transplantation
  • liver transplantation
  • outcome assessment
  • plasmapheresis
  • priority journal
  • regulator protein
  • review
  • steroid

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Kavanagh D.

  • Goodship T.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free